The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in preparing a drug for treating urothelial carcinoma. The drug is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival time of the patients.
本发明涉及使用抗 HER2
抗体-药物共轭物(ADC)制备治疗尿路上皮癌的药物。该药物对尿路上皮癌患者,尤其是局部晚期或转移性尿路上皮癌患者安全有效,能有效延长患者的生存时间。